FY2024 EPS Estimates for Liquidia Boosted by HC Wainwright

Liquidia Co. (NASDAQ:LQDA) – Investment analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Liquidia in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($1.51) per share for the year, up from their prior forecast of ($1.54). HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Liquidia’s FY2025 earnings at ($1.62) EPS and FY2028 earnings at ($0.16) EPS.

A number of other research firms have also issued reports on LQDA. Raymond James upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. Lifesci Capital began coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price on the stock. BTIG Research reduced their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, August 19th. Scotiabank assumed coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Liquidia in a report on Thursday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Liquidia Stock Down 1.8 %

Liquidia stock opened at $9.84 on Monday. Liquidia has a 52 week low of $6.10 and a 52 week high of $16.99. The firm’s 50-day simple moving average is $10.52 and its 200 day simple moving average is $11.48. The firm has a market capitalization of $832.86 million, a PE ratio of -6.04 and a beta of 0.21.

Hedge Funds Weigh In On Liquidia

Several large investors have recently added to or reduced their stakes in LQDA. Quest Partners LLC bought a new position in Liquidia during the second quarter worth $27,000. Hilltop National Bank bought a new position in Liquidia during the second quarter worth $33,000. Clear Harbor Asset Management LLC bought a new position in Liquidia during the third quarter worth $100,000. Signaturefd LLC lifted its stake in Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after purchasing an additional 9,984 shares during the last quarter. Finally, Ballentine Partners LLC bought a new position in Liquidia during the third quarter worth $110,000. 64.54% of the stock is currently owned by institutional investors.

Insider Transactions at Liquidia

In other news, General Counsel Russell Schundler sold 2,576 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the sale, the general counsel now owns 486,048 shares of the company’s stock, valued at approximately $5,399,993.28. This trade represents a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Caligan Partners Lp purchased 150,000 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were bought at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the transaction, the director now directly owns 6,994,997 shares of the company’s stock, valued at approximately $66,522,421.47. This represents a 2.19 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 21,551 shares of company stock valued at $236,021. 30.10% of the stock is currently owned by corporate insiders.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).